Soliris to Stop Immune-Mediated Death in COVID-19 (SOLID-C19)—A Compassionate-Use Study of Terminal Complement Blockade in Critically Ill Patients with COVID-19-Related Adult Respiratory Distress Syndrome
Thomas C. Pitts
Abstract
Eculizumab, a terminal complement (C5)-inhibiting monoclonal antibody, was administered in five mechanically ventilated patients in life-threatening condition due to COVID-19-related acute respiratory distress syndrome (ARDS) between 23 March 2020 and 3 April 2020. Their clinical progress was monitored. The primary endpoint was mortality. One patient was excluded while two passed away. The remaining two patients survived. At the time of this study, the mortality rate in mechanically ventilated COVID-19 patients suffering from ARDS receiving the standard of care as their therapeutic regimen was reportedly as high as 97%. This pilot study demonstrates a 50% mortality rate in patients receiving eculizumab therapy.
Topics & Concepts
ARDSMedicineEculizumabIntensive care medicineCoronavirus disease 2019 (COVID-19)Mortality rateTocilizumabRegimenInternal medicineImmunologyLungImmune systemComplement systemDiseaseInfectious disease (medical specialty)Complement system in diseasesSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies